Table 5.
Comparison of radiotherapy interruptions, chemotherapy completion and treatment deaths seen in the ACT2 publication, all UK audit patients, UK audit patients undergoing ACT2 regimen and UK audit patients treated in keeping with UK intensity-modulated radiotherapy (IMRT) guidance
| Percentage (with 95% confidence interval) | ACT2 trial | All UK audit patients | Two-phase conformal CRT in UK audit | IMRT as per guidance in UK audit |
|---|---|---|---|---|
| n | 940∗ | 242 | 52 | 157 |
| Radiotherapy courses with interruptions | 15% | N/A† | 4 (8%) | 7 (4%) |
| Patients completing planned radiotherapy dose (irrelevant of gaps) | N/R | 227 (94%) | 47 (90%) | 150 (96%) |
| Patients completing planned chemotherapy | 77% | 201 (83%) | 45 (87%) | 131 (83%) |
| Treatment deaths | <1% | 2 (1%) | 2 (4%) | 0 |
∗
Data from all patients within ACT2 were used for comparison as data for specific groups were not available.
†
As includes palliative and lower dose patients not calculated.